Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03849625
  4. Details
NCT03849625 Clinical Trial

Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand

Aspirin-exacerbated Respiratory Disease Clinical Trial

Official title:
Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03849625
Other study ID # Chula-ARC 002/13
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2015
Est. completion date March 31, 2020

Study information
Verified date February 2022
Source Chulalongkorn University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Study clinical characteristics and phenotypes of patients diagnosed with NSAID sensitivity in Thailand

Recruitment information / eligibility
Status Completed
Enrollment 158
Est. completion date March 31, 2020
Est. primary completion date February 28, 2020
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Thai patients with a history of an immediate reaction to aspirin/paracetamol, or NSAIDs visiting King Chulalongkorn memorial Hospital Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• aspirin, NSAIDs, paracetamol
Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases

Locations
Country Name City State
Thailand Faculty of Medicine, Chulalongkorn University Bangkok

Sponsors (1)
Lead Sponsor Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

References & Publications (1)

Klaewsongkram J, Buranapraditkun S, Mongkolpathumrat P, Palapinyo S, Chantaphakul H. Clinical Characteristics, Urinary Leukotriene E4 Levels, and Aspirin Desensitization Results in Patients With NSAID-Induced Blended Reactions. Allergy Asthma Immunol Res. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Results of skin test/provocation test Positive, negative, or equivocal 4 years
Secondary Phenotypes of allergic reactions 4 years
Secondary Urine leukotriene E4 4 years
See also
  Status Clinical Trial Phase
Completed NCT03595488 - Dupilumab for Aspirin-exacerbated Respiratory Disease Phase 2
Enrolling by invitation NCT03627481 - Sleep Quality After Nasosinusal Surgery in AERD Patients N/A
Recruiting NCT05672030 - Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Recruiting NCT05031455 - Mechanisms of Dupilumab in AERD Phase 2
Active, not recruiting NCT03973749 - Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD N/A
Recruiting NCT04147013 - Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients With CRS Phase 4
Completed NCT01631773 - A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only N/A
Recruiting NCT05575037 - Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease Phase 2
Completed NCT03326063 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Phase 2